Celgene's arthritis drug shows potential in Phase II trial
This article was originally published in Scrip
Executive Summary
Celgene's apremilast improves outcomes in psoriatic arthritis patients, according to top-line data from a Phase II trial. The US-based company plans to initiate pivotal Phase III studies.